The present relates to methods for treating a disease, and methods to reduce the formation of anti Drug (ADA) in response to the Administration of a Therapeutic Agent.Also refers to methods for treating a disease, in particular a cell proliferative disorder BAnd Methods for reducing adverse effects in response to the Administration of a Therapeutic Agent, in particular a Therapeutic Agent Activator of t cells.Claim 1: a type II anti-cd20 Antibody for use in a method for treating a disease in a subjectThe Method comprises a Treatment regime that includes (i) the Administration on the subject of anti-cd20 Antibody Type IIAnd consecutively over a period of time, (ii) subject to the Administration of a Therapeutic Agent.Where the period of time between the Administration of anti-cd20 Antibody of Type II and the Administration of the therapeutic Agent is sufficient to reduce the number of B cells in the Snap hooIn response to the Administration of anti-cd20 Antibody of Type II.Claim 5: a type II anti-cd20 Antibody for use in a method for (i) reduce the formation of anti Drug (ADA) against a Therapeutic Agent in a subject and / or (ii) ReducingThe release of cytokines associated with the Administration of a Therapeutic Agent, in particular a Therapeutic Agent Activator of t cells in a subject.Comprising Administration of anti-cd20 Antibody Type II to the subject before the Administration of the therapeutic Agent.La presente se refiere a métodos para tratar una enfermedad, y a métodos para reducir la formación de anticuerpos anti-fármaco (ADA) en respuesta a la administración de un agente terapéutico. Se refiere además a métodos para tratar una enfermedad, en particular un trastorno proliferativo de células B, y a métodos para la reducción de los efectos adversos en respuesta a la administración de un agente terapéutico, en particular un agente terapéutico activador de células T. Reivindicación 1: Un anticuerpo anti-CD20 de tipo II para su uso en un método para tratar una
